Sirtinol
(Synonyms: 2-[[(2-羟基-1-萘基)亚甲基]氨基]-N-(1-苯基乙基)苯甲酰胺) 目录号 : GC14945
Inhibitor of sirtuin deacetylases
Cas No.:410536-97-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Kinase experiment [1]: | |
|
In vitro inhibition of human Sirt2 activity |
1.5 μg of recombinant human GST-Sirt2 (amino acids 18 ~ 340) were incubated at 30 °C for 2 hrs in 50 μL of assay buffer (50 mM Tris-HCl, pH 8.8, 4 mM MgCl2, 0.2 mM dithiothreitol with different concentrations of Sirtinol, 50 μM NAD, and tritiated acetylated HeLa histones (1000 cpm), purified by acid extraction). HDAC activity was determined by scintillation counting of the ethyl acetate-soluble [3H]acetic acid. |
| Cell experiment [2]: | |
|
Cell lines |
LNCaP, 22Rv1, DU145 and PC3 cells |
|
Preparation method |
The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20 °C for several months. |
|
Reaction Conditions |
30 or 120 μM; 24 or 48 hrs |
|
Applications |
Sirtinol (30 and 120 μM) treatment for 24 or 48 hrs significantly decreased the growth and viability of the entire PCa cell lines tested. |
| Animal experiment [3]: | |
|
Animal models |
Male SD rats subjected to trauma-hemorrhage |
|
Dosage form |
1 mg/kg; i.v. |
|
Applications |
At the dose of 1 mg/kg, Sirtinol attenuated pro-inflammatory cytokine production and protected against hepatic injury following trauma-hemorrhage in male SD rats. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Grozinger CM, Chao ED, Blackwell HE, Moazed D, Schreiber SL. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J Biol Chem. 2001 Oct 19;276(42):38837-43. [2]. Jung-Hynes B, Nihal M, Zhong W, Ahmad N. Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition? J Biol Chem. 2009 Feb 6;284(6):3823-32. [3]. Liu FC, Day YJ, Liou JT, Lau YT, Yu HP. Sirtinol attenuates hepatic injury and pro-inflammatory cytokine production following trauma-hemorrhage in male Sprague-Dawley rats. Acta Anaesthesiol Scand. 2008 May;52(5):635-40. | |
Sirtinol is an inhibitor of SIRT with IC50 value of 48.6 μM (24 h) and 43.5 μM (48 h) in MCF-7 cells [1].
Sirtinol significantly reduces the growth of MCF-7 cells in a concentration- and time-dependent manner. Meanwhile, the expression level of SIRT1 is notably decreased by sirtinol results in an induction of acetylated p53. It is found that sirtinol decreases the the expression of cell cycle-regulated proteins such as cyclin B1, cyclin D1, CDK2 and CDK6 and subsequently induces G1 phase arrest which indicates cell apoptosis. Furthermore, sirtinol is also demonstrated to induce autophagy in MCF-7 cells. Other in vitro assays show that sirtinol inhibits SIRT2 (amino acids 18–340) with IC50 value of 45 μM while it does not inhibit HDAC1 at 50 and 100 μM [1, 2].
Reference:
[1] Wang J, Kim TH, Ahn MY, Lee J, Jung JH, Choi WS, Lee BM, Yoon KS, Yoon S, Kim HS. Sirtinol, a class III HDAC inhibitor, induces apoptotic and autophagic cell death in MCF-7 human breast cancer cells. Int J Oncol. 2012 Sep;41(3):1101-9.
[2] Grozinger CM, Chao ED, Blackwell HE, Moazed D, Schreiber SL. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J Biol Chem. 2001 Oct 19;276(42):38837-43.
| Cas No. | 410536-97-9 | SDF | |
| 别名 | 2-[[(2-羟基-1-萘基)亚甲基]氨基]-N-(1-苯基乙基)苯甲酰胺 | ||
| 化学名 | 2-[[(Z)-(2-oxonaphthalen-1-ylidene)methyl]amino]-N-(1-phenylethyl)benzamide | ||
| Canonical SMILES | CC(C1=CC=CC=C1)NC(=O)C2=CC=CC=C2NC=C3C(=O)C=CC4=CC=CC=C43 | ||
| 分子式 | C26H22N2O2 | 分子量 | 394.47 |
| 溶解度 | ≥ 19.7 mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.535 mL | 12.6752 mL | 25.3505 mL |
| 5 mM | 0.507 mL | 2.535 mL | 5.0701 mL |
| 10 mM | 0.2535 mL | 1.2675 mL | 2.535 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。